| Identification | Back Directory | [Name]
GLP-1 receptor agonist 4 | [CAS]
1187061-62-6 | [Synonyms]
GLP-1 receptor agonist 4
[1,1'-Biphenyl]-4-propanoic acid, 4'-cyano-α-[[[(3R,8S)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2,3,6,7,8,9-hexahydro-1-methyl-2-oxo-7-[(1S)-1-phenylpropyl]-1H-pyrido[4,3-g][1,4]benzoxazin-8-yl]carbonyl]amino]-, (αS)- | [Molecular Formula]
C51H44Cl2N4O6 | [MDL Number]
MFCD34469613 | [MOL File]
1187061-62-6.mol | [Molecular Weight]
879.82 |
| Hazard Information | Back Directory | [Uses]
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes[1]. | [References]
[1] Adnan M.M. Mjalli,et al. Oxadiazoanthracene compounds for the treatment of diabetes. WO2009111700A2. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|